Dupilumab is a mAb against IL-4/IL-13 for the treatment of severe AD in children >12 years of age, for the treatment of moderate-severe uncontrolled asthma with type 2 inflammation, and for severe AD. Here, IL13 is linked to Alzheimer disease.